CLASS II Drug recall · Reported 29 Jan 2020 · FDA Enforcement Report

Ranitidine Tablets, USP 300 mg a) recalled by Denton Pharma

Denton Pharma is recalling Ranitidine Tablets, USP 300 mg a), distributed nationwide in the US. The recall was initiated on 20 Dec 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesa). N106851901, Exp. 11/30/2021 N106851902, Exp. 10/31/2021 b). C106851901, Exp. 11/30/2021 C106851902 Exp. 10/31/2021 C106851903 Exp. 02/28/2022 C106851904 Exp. 11/30/2021 C106851905 Exp. 05/31/2022
Quantity recalled467 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0795-2020
FDA event ID
84657
Recalling firm
Denton Pharma, North Blenheim, NY
Classification
Class II
Status
Terminated
Recall initiated
20 Dec 2019
FDA classified
20 Jan 2020
Reported
29 Jan 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

20 Dec 2019Recall initiated by company
20 Jan 2020Classified by FDA+31 days
29 Jan 2020Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Ranitidine Tablets, USP 300 mg a). 15-count bottles (NDC 70934-287-15), b). 90-count bottles (NDC 70934-287-90), Rx Only, Repackaged by: Northwind Pharmaceuticals North Brenheim, NY 12131

Where it was distributed

Nationwide

Nationwide

Questions about this recall

Is Ranitidine Tablets, USP 300 mg a) recalled?

Yes. Denton Pharma recalled Ranitidine Tablets, USP 300 mg a) on 20 Dec 2019. The recall is Class II and its status is Terminated. Recall number D-0795-2020.

Why was it recalled?

CGMP Deviations: Presence of NDMA impurity detected in product.

Which lots are affected?

a). N106851901, Exp. 11/30/2021 N106851902, Exp. 10/31/2021 b). C106851901, Exp. 11/30/2021 C106851902 Exp. 10/31/2021 C106851903 Exp. 02/28/2022 C106851904 Exp. 11/30/2021 C106851905 Exp. 05/31/2022

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Denton Pharma

All 4

Other Ranitidine recalls

All 34